MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Delcath Systems EBITDA 2011-2026 | DCTH
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Delcath Systems
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 898 K | -12.3 M | -38.1 M | -33.7 M | -24.4 M | -24 M | -18.1 M | -26.6 M | -17.9 M | -16.1 M | -14.6 M | -18.3 M | -31.9 M | -52.5 M | -45.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 898 K | -52.5 M | -24.9 M |
Quarterly EBITDA Delcath Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -288 K | 2.69 M | 685 K | - | -1.16 M | -3.81 M | -10.2 M | - | -10.5 M | -7.9 M | -8.3 M | - | -8.07 M | -9.39 M | -8.31 M | - | -6.58 M | -6.37 M | -6.69 M | - | -4.86 M | -4.18 M | -5.03 M | - | -5.47 M | -4.03 M | -5.61 M | - | -5.69 M | -5.99 M | -7.38 M | -4.72 M | -4.53 M | -4.5 M | -4.14 M | -4.38 M | -4.62 M | -3.77 M | -3.38 M | -4.23 M | -3.55 M | -3.42 M | -3.51 M | -3.28 M | -4.85 M | -5.6 M | -4.81 M | -5.53 M | -6.4 M | -10.3 M | -9.9 M | -11.8 M | -11.9 M | -14.9 M | -14.2 M | 16 M | 12.9 M | 10.9 M | 8.03 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16 M | -14.9 M | -4.55 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
753 M | $ 190.07 | 2.73 % | $ 14.2 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 12.66 | 0.64 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.49 | -2.79 % | $ 131 M |  France |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 64.23 | 1.28 % | $ 95.1 B | USA |
 |
Electromed
ELMD
|
10.7 M | $ 26.06 | 2.64 % | $ 220 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.66 | 8.2 % | $ 41.1 M | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.79 | 12.29 % | $ 334 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 16.75 | 1.33 % | $ 393 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
LENSAR
LNSR
|
-21 M | $ 5.93 | 2.24 % | $ 70.9 M | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
757 M | $ 95.25 | 2.7 % | $ 12.9 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.12 | 2.91 % | $ 1.29 M | USA |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 5.45 | 3.02 % | $ 1.15 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
-9.55 M | $ 6.82 | 3.49 % | $ 181 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.06 | 1.92 % | $ 18 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 57.59 | 2.02 % | $ 1.69 B | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 39.08 | 3.09 % | $ 1.21 B | USA |
 |
LivaNova PLC
LIVN
|
228 M | $ 67.12 | 3.25 % | $ 3.66 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
352 M | $ 90.2 | 2.07 % | $ 3.13 B | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.8 | 0.21 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 80.99 | 2.45 % | $ 47.4 B | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.7 | 0.75 % | $ 7.49 M | USA |
 |
Penumbra
PEN
|
207 M | $ 332.13 | 0.2 % | $ 12.9 B | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |